{
}
Barclays analysts see potential upside in Sandoz AG shares, believing tariff risks are largely priced in. Despite underperforming the European pharmaceutical sector, Sandoz's long-term growth is supported by its biosimilar pipeline, with a revised price target of CHF 46.50 per share. Upcoming product launches and strategic investments in manufacturing are expected to drive future growth, although challenges like price erosion in the generics market persist.
UBS Global Research has downgraded Sandoz to "neutral," citing limited upside in biosimilar growth and a forecasted 3% lower growth rate than consensus estimates. Despite a strong share price performance, analysts anticipate potential downside to 2025 projections, with Sandoz's biosimilar sales expected to fall 2% below consensus. The firm has raised Sandoz's target price to CHF 44 due to foreign exchange adjustments, while litigation risks and slower growth in generics pose challenges ahead.
The Canadian generic drug market is projected to grow from $9.4 billion in 2023 to $19.5 billion by 2033, driven by the increasing demand for affordable medications and the expansion of product portfolios by pharmaceutical companies. Retail pharmacies lead the market, supported by the prevalence of generic drugs, particularly in oncology and oral administration. Key players include Apotex, Teva, and Mylan, with ongoing developments such as new product launches and acquisitions shaping the competitive landscape.
Sandoz AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
barclays sees growth potential in sandoz despite tariff concerns and market challenges
12:05 02.04.2025
ubs downgrades sandoz to neutral amid biosimilar growth concerns
13:16 03.02.2025
canadian generic drug market projected to reach 19.5 billion by 2033
Canadian Dollar
Teva Pharmaceutical Industries Limited
Apotex Inc.
Pharmascience Inc. SA
Mylan Pharmaceuticals ULC
Sandoz AG
CAN
Pharmascience Inc.
Apotex Inc.
Sunshine Biopharma
Mylan Pharmaceuticals ULC
Sandoz AG
Show more
04:17 19.11.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Banking Regulations
Global Financial Events
Workplace Trends
Retail and Consumer Goods
CEO Changes
Market Analysis and Predictions
Central Bank Actions
Global Trade Developments
Startups & Entrepreneurship
Government Policies
Government Economic Policies
Domestic Politics
Financial Scams and Security
Corporate Social Responsibility
Private Equity Deals
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
Barclays PLC
UniCredit S.p.A.
Deutsche Bank Money Market PP
Credit Suisse Lux Digital Healt
Banco BPM S.p.A.
Bank of America Corporation
BNP Paribas SA
UBS Group AG
Apple Inc.
The Goldman Sachs Group, Inc.
Commerzbank AG
CREDIT AGRICOLE
Wells Fargo & Company
Credit Suisse Strategic Income I
Banco Santander, S.A.
Lloyds Banking Group plc
Amazon.com, Inc.
SpaceXCoin USD
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Danish Krone
Hong Kong Dollar
Australian Dollar
Offshore Chinese Yuan
Singapore Dollar
Canadian Dollar
Mexican Peso
Norwegian Krone
Indonesian Rupiah
Russian Ruble
Chilean Peso
United Arab Emirates Dirham
People: